Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events

References

• World Health Organization. Global report on psoriasis [Internet]. World Health Organization; 2016. [cited 2020 Apr 13]. Available from: https://apps.who.int/iris/handle/10665/204417.
   Google Scholar
• Dubertret L, Mrowietz U, Ranki A, EUROPSO patient survey, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155(4):729–736.
   PubMed Web of Science ®Google Scholar
• Kivelevitch D, Frieder J, Watson I, et al. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. Expert Opin Pharmacother. 2018;19(6):561–575.
   PubMed Web of Science ®Google Scholar
• Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17–26.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356.
   PubMed Web of Science ®Google Scholar
• Kim H-S, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33(34):e213–e213.
   PubMed Web of Science ®Google Scholar
• Eaglstein WH. Real-world evidence – what is it and does it matter for approval of drugs? J Am Acad Dermatol. 2018;79(2):390–391.
   PubMed Web of Science ®Google Scholar
• Lee EB, Pithadia DJ, Reynolds KA, et al. Real-world drug survival of ixekizumab for psoriasis. J Am Acad Dermatol. 2019;81(1):270–272.
   PubMed Web of Science ®Google Scholar
• Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019;33(3):553–559.
   PubMed Web of Science ®Google Scholar
• Magdaleno-Tapial J, Carmena-Ramón R, Valenzuela-Oñate C, et al. Efficacy and safety of ixekizumab in a real-life practice: a retrospective bicentric study. Actas Dermo-Sifiliográficas Engl. Ed. 2019;110(7):585–589.
   PubMed Web of Science ®Google Scholar
• Krishnan E, Fries JF. Measuring effectiveness of drugs in observational databanks: promises and perils. Arthritis Res Ther. 2004;6(2):41–44.
   PubMed Web of Science ®Google Scholar
• Shalom G, Cohen AD, Ziv M, et al. Biologic drug survival in Israeli psoriasis patients. J. Am Acad Dermatol. 2017;76(4):662–669.e1.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Dam TN, et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091–1096.
   PubMed Web of Science ®Google Scholar
• Reek JMPA, Lümig PPM, Driessen RJB, et al. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Br J Dermatol. 2014;170(2):415–424.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158.
   PubMed Web of Science ®Google Scholar
• Zweegers J, van den Reek J, van de Kerkhof PCM, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175(2):340–347.
   PubMed Web of Science ®Google Scholar
• Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736–740.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729–735.
   PubMed Web of Science ®Google Scholar
• Reich K, Krüger K, Mössner R, et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040–1047.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.e1–573.e13.
   Web of Science ®Google Scholar
• Gottlieb AB, Lacour J-P, Korman N, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. J Eur Acad Dermatol Venereol. 2017;31(4):679–685.
   PubMed Web of Science ®Google Scholar
• Blonde L, Khunti K, Harris SB, et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther. 2018;35(11):1763–1774.
   PubMed Web of Science ®Google Scholar